Innovent Biologics, Inc.
IVBXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 6.00 | 0.97 | 0.90 | -0.13 |
| FCF Yield | -0.81% | -2.27% | -7.49% | -6.83% |
| EV / EBITDA | -98.12 | -72.70 | -26.44 | -24.36 |
| Quality | ||||
| ROIC | -5.16% | -8.68% | -20.90% | -20.56% |
| Gross Margin | 83.97% | 70.89% | 79.57% | 86.58% |
| Cash Conversion Ratio | -13.60 | -0.13 | 0.88 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 27.40% | 13.28% | 5.83% | 59.74% |
| Free Cash Flow Growth | 66.14% | 62.56% | 14.77% | -258.73% |
| Safety | ||||
| Net Debt / EBITDA | 9.74 | 9.73 | -1.26 | -0.48 |
| Interest Coverage | -11.17 | -17.03 | -30.71 | -43.28 |
| Efficiency | ||||
| Inventory Turnover | 1.84 | 1.87 | 0.65 | 0.43 |
| Cash Conversion Cycle | 172.96 | 179.46 | 505.58 | 834.91 |